Cassandra Protocol
S01E22 : IN-VIVO GENE SURGERY 2/3 : BEAM THERAPEUTICS
The file bled through the architecture. Act One of a systemic biotech collapse is written in the liver. Welcome to the Cassandra Protocol. Watch it burn.
In-vivo Gene Surgery
Beam Therapeutics
AUDIT: Beam Therapeutics: The Clinical Dead Zone
A forensic audit of Beam Therapeutics (BEAM-302) reveals severe liver toxicity, a 12-month FDA hold, and executive de-risking in the gene surgery space.
Biotech Bubble
NOTES: Beam Therapeutics: Editing The Ghost Engine
Beam Therapeutics is selling a gene-editing miracle, but with toxic livers and a CEO cashing out, the banana stand is burning. A brutal look at the spin.
Cassandra Protocol
S01E16 : IN-VIVO GENE SURGERY 1/3 : INTELLIA
The server room hums a frequency that shouldn't exist. The Cassandra Protocol decrypts the Gene Surgery Archive. We are logging the biological debt.
Intellia Therapeutics
AUDIT: Intellia: The Biological API & the Sepsis Pivot
Audit of Intellia Therapeutics' in-vivo CRISPR trials. Examining the MAGNITUDE Phase 3 data, the 'Sepsis Pivot', and the severe clinical solvency risks.
Tech Fail
NOTES: Intellia: A Cure So Good It Might Bankrupt You
Intellia promises a one-time genetic cure, but their CRISPR tech is like throwing a spanner in a Swiss watch. Unpacking the Ostrich Algorithm and spin.